WAVE Life Sciences Ltd (WVE)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013370)
◆英語タイトル:WAVE Life Sciences Ltd (WVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013370
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:44
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
WAVE Life Sciences Ltd (WAVE), formerly WAVE Life Sciences Pte Ltd is a genetic medicine company that develops stereopure nucleic acid therapies. The company’s pipeline products comprise multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi, among others. It utilizes its proprietary synthetic chemistry platform to design, develop and commercialize nucleic acid therapeutics. The company’s stereopure nucleic acid therapeutics are developed to affect the production of disease associated proteins and target rare genetic diseases. It controls the orientation of the chemical linkages. WAVE is headquartered in Cambridge, Massachusetts, the US.

WAVE Life Sciences Ltd (WVE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
WaVE Life Sciences Raises USD66 Million in Series B Financing Round 10
WaVe Life Sciences Raises USD18 Million in Series A Financing 12
Partnerships 13
ReadCoor and WAVE Life Sciences Enter into Research Agreement 13
nLife Therapeutics Enters into Research Agreement with WAVE Life Sciences 14
Wave Life Sciences Enters into Research Agreement with University of Dundee 15
Wave Life Sciences Enters into Licensing Agreement with Max Planck Innovation 16
Wave Life Sciences Enters into Research Agreement with Children’s Hospital of Philadelphia 18
Wave Life Sciences Enters into Research Agreement with University of Oxford 19
Licensing Agreements 20
Pfizer Enters into Licensing Agreement with WAVE Life Sciences 20
Equity Offering 21
WAVE Life Sciences Prices Public Offering of Shares for USD100 Million 21
Wave Life Sciences Completes IPO For USD111.9 Million 23
WAVE Life Sciences Ltd – Key Competitors 25
WAVE Life Sciences Ltd – Key Employees 26
WAVE Life Sciences Ltd – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 09, 2017: Wave Life Sciences Reports Second Quarter 2017 Financial Results and Provides Business Update 28
May 10, 2017: WAVE Life Sciences Reports First Quarter 2017 Financial Results and Provides Business Update 30
Mar 16, 2017: WAVE Life Sciences Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Business Update 32
Nov 09, 2016: WAVE Life Sciences Reports Third Quarter 2016 Financial Results and Provides Business Update 34
Aug 15, 2016: WAVE Life Sciences Reports Second Quarter 2016 Financial Results and Provides Business Update 36
May 16, 2016: WAVE Life Sciences Reports First Quarter 2016 Financial Results and Provides Business Update 38
Mar 30, 2016: WAVE Life Sciences Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update 39
Corporate Communications 40
Nov 10, 2016: WAVE Life Sciences Appoints Christian Henry to its Board of Directors 40
Aug 17, 2016: WAVE Life Sciences Appoints Keith Regnante as Chief Financial Officer 41
Product News 42
01/06/2017: WAVE Life Sciences Provides Update on Duchenne Muscular Dystrophy Program WVE-210201 42
Other Significant Developments 43
May 09, 2016: WAVE Life Sciences to Advance Next-Generation Nucleic Acid Therapies to Address Unmet Need in Duchenne Muscular Dystrophy 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
WAVE Life Sciences Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
WAVE Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
WaVE Life Sciences Raises USD66 Million in Series B Financing Round 10
WaVe Life Sciences Raises USD18 Million in Series A Financing 12
ReadCoor and WAVE Life Sciences Enter into Research Agreement 13
nLife Therapeutics Enters into Research Agreement with WAVE Life Sciences 14
Wave Life Sciences Enters into Research Agreement with University of Dundee 15
Wave Life Sciences Enters into Licensing Agreement with Max Planck Innovation 16
Wave Life Sciences Enters into Research Agreement with Children’s Hospital of Philadelphia 18
Wave Life Sciences Enters into Research Agreement with University of Oxford 19
Pfizer Enters into Licensing Agreement with WAVE Life Sciences 20
WAVE Life Sciences Prices Public Offering of Shares for USD100 Million 21
Wave Life Sciences Completes IPO For USD111.9 Million 23
WAVE Life Sciences Ltd, Key Competitors 25
WAVE Life Sciences Ltd, Key Employees 26
WAVE Life Sciences Ltd, Subsidiaries 27

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ WAVE Life Sciences Ltd (WVE)-製薬・医療分野:企業M&A・提携分析(WAVE Life Sciences Ltd (WVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆